Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Completed · Phase 3 · Has a placebo group

Conditions studied: Dyslipidemia

In brief

This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.

Key facts

Study ID
NCT02207634
Run by
Amgen
People needed
1974
Starts
2014-09-10
Expected to finish
2016-11-11
Last updated by the study team
2018-01-16

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.